Xoojinta Daaweynta Unugyada Killer ee Dabiiciga ah si loola dagaallamo Kansarka

Isleworth Healthcare Acquisition Corp. iyo Cytovia Holdings, Inc. ayaa maanta ku dhawaaqay inay galeen heshiis ganacsi oo isku-dar ah oo qeexan. Marka la dhammeeyo isku-darkan, Isleworth waxaa loo bedeli doonaa Cytovia Therapeutics, Inc. ("shirkadda isku-dhafka ah") iyo saamiyadeeda guud iyo dammaanad qaadka ayaa la filayaa inay ku sii jiraan liiska NASDAQ ee hoos yimaada calaamadaha calaamadaha INKC iyo INKCW, siday u kala horreeyaan.               

Shirkadda isku dhafka ah waxay sii wadi doontaa hawlaha Cytovia waxayna diiradda saari doontaa horumarinta iyo soo saarista unugyada NK ee dhammaystiran iyo NK hawlwadeennada ka hortagga unugyada.

Shirkadda isku dhafka ah waxaa hogaamin doona Dr. Daniel Teper, Co-Founder, Guddoomiyaha, iyo Madaxa Fulinta ee Cytovia.

"Waxaan ka mahadcelineynaa taageerada xooggan ee ka timid maalgashadayaasha cusub iyo kuwa hadda jira iyo kooxda hal-abuurka leh ee Isleworth. Waxaan filaynaa in macaamil ganacsigu uu dardargeliyo fulinta aragtida Cytovia si loo horumariyo daweynta NK ee daaweynta kansarka” ayuu yiri Dr. Teper. "Waxaa na dhiirigeliyay xogtayada caafimaad ee dhowaan lagu soo bandhigay AACR, taas oo taageerta horumarinta unugyada NK ee iPSC-ga (iNK) iyo hawl-wadeennada unugyada Flex-NK ™ ee daaweynta Hepatocellular Carcinoma." 

Bob Whitehead, Maamulaha Isleworth, wuxuu yiri: "Isleworth waxay qiimeysay shirkado badan oo sayniska nolosha ah waxaana aad ula dhacay kartida iyo tignoolajiyada ay soo aruurisay Cytovia. Waxaan aaminsanahay in Cytovia ay tahay mid ka mid ah kuwa ugu horumarsan, shirkadaha daweynta unugyada hal-abuurka leh ee ku lug leh horumarinta daawaynta kansarka cusub. Daawaynta unugga ee Oncology waxay mar hore rajo u keentay malaayiin. Hababka Cytovia waxay si macquul ah u samayn karaan habab la mid ah kuwa ku habboon 'off-the-shelf' oo la awoodi karo."

Habka Daaweynta Cytovia

Cytovia waxay rabta in ay dardargeliso helitaanka bukaan-socodka ee daaweynta unugyada beddelka ah iyo daawaynta difaaca jirka, iyada oo wax ka qabanaysa dhowr ka mid ah baahiyaha caafimaad ee ugu adag ee aan la daboolin ee Oncology.

Shirkaddu waxa ay diiradda saartaa ka faa'iidaysiga habka difaaca jidhka iyada oo horumarinaysa unugyada NK-unuga oo dhammaystiran oo carqaladaynaya iyo aaladaha lidka-jirka ee NK-ga. Gaar ahaan, Cytovia waxay horumarinaysaa saddex nooc oo unugyo iNK ah: unugyo iNK ah oo aan la tafatirin, unugyada TALEN® hiddo-wadaha iNK oo leh shaqo horumarsan iyo adkaysi, iyo TALEN beegsiga. Tiknoolajiyada labaad ee dhammaystirka ah waa madal ka hortag ah oo kala duwan oo afar geesle ah oo loogu talagalay in lagu hawlgeliyo unugyada NK iyada oo la beegsanayo soo-dhoweynta NKp46 ee firfircoonida iyada oo la adeegsanayo tignoolajiyada Flex-NK ™ iska leh.

Labadan aaladood ee tignoolajiyada ayaa loo isticmaalay in lagu horumariyo daawaynta bukaanada qaba Hepatocellular Carcinoma (HCC) iyo burooyinka adag. Daraasadaha caafimaadka ayaa la filayaa inay bilaabmaan dhammaadka 2022.

Xarunteedu tahay Aventura, FL, Cytovia waxay ka shaqeysaa shaybaarada R&D ee Natick, MA iyo xarun wax soo saar oo unug cGMP ah oo ku taal Puerto Rico waxayna leedahay iskaashi cilmiyeed oo lala yeesho Cellectis, CytoImmune Therapeutics, Jaamacadda Cibraaniga ee Yeruusaalem, INSERM, New York Stem Cell Foundation, Qaranka Qaranka Machadka Kansarka, iyo Jaamacadda California San Francisco (UCSF). Cytovia Therapeutics waxay dhawaan samaysay CytoLynx Therapeutics, iskaashi istaraatiijiyadeed oo diiradda lagu saaray cilmi-baarista iyo horumarinta, wax soo saarka, iyo hawlaha ganacsi ee Shiinaha Weyn iyo wixii ka dambeeya.

Dhuumaha Cytovia

Cytovia waa shirkaddii ugu horreysay ee difaaca-oncology leh oo leh awood ay isugu geyso hiddo-wadaha la tafatiray ee iPSC-ka-soo-baxa NK Cell iyo Flex-NK™ unugga ka-hortagga unugyada si loo horumariyo jiilka soo socda ee daaweynta tallaalka difaaca ee labadaba burooyinka dhiigga iyo kuwa adag.

Cytovia's portfolio waxaa ku jira bartilmaameedyo iyo tilmaamo leh muuqaal khatar ah oo dheellitiran.

GPC3 waa bartilmaameed cusub oo rajo leh oo loogu talagalay burooyinka adag, gaar ahaan kansarka hepatocellular, halkaasoo baahida caafimaad ee aan la daboolin ay tahay tan ugu muhiimsan. Barnaamijka hogaanka Cytovia wuxuu higsanayaa inuu horumariyo daawaynta heerka koowaad ee HCC ee lagu beegsanayo GPC3. Afarta musharrax ee bilowga ah waxaa loo qiimeyn doonaa sida monotherapies iyo sida daawaynta isku dhafan. CYT-303, Cytovia's GPC3 Flex-NK™ hawlgeliyaha, waa unug saddex-gaar ah oo ka hortag ah oo ku xidha unugyada burooyinka HCC iyada oo loo marayo GPC3 iyo unugyada NK iyada oo loo marayo NKp46 iyo CD16a. Bukaanada qaba nambarka daciifka ah ama shaqada unugyada NK, Cytovia waxay qiimeyn doontaa isku darka unugyada iNK, CYT-100, si ay suurtogal u tahay inay furto awoodda buuxda ee istaraatiijiyadan daaweynta. Cytovia waxay sidoo kale horumarinaysaa CYT-150, unugyada iNK hiddo-wadaha, si loo hagaajiyo galitaanka burada iyo joogteynta unugyada, taas oo sidoo kale lagu dari karo CYT-303. Intaa waxaa dheer, CYT-503, GPC3-bartilmaameedka daaweynta unugyada CAR-iNK, waxaa loogu talagalay in lagu wanaajiyo gaar ahaan bartilmaameedsiga burada. Cytovia waxay rajaynaysaa inay buuxiso INDs CYT-303 iyo CYT-100, oo ay ku xigto INDs CYT-150 iyo CYT-503.

CD38 waa bartilmaameed caafimaad iyo ganacsi oo si wanaagsan loo aasaasay oo loogu talagalay Multiple Myeloma. Cytovia waxay horumarinaysaa CYT-338 iyo CYT-538 kuwaas oo ah, siday u kala horreeyaan, CD38-bartilmaameedka hawl-wadeennada unugyada Flex-NK™ iyo unugyada CAR-iNK ee daawaynta Multiple Myeloma ee bukaannada ku guuldareystay CD38 daawaynta antibody iyo wakiilada beegsanaya korriinka unugyada B antigen (BCMA).

Cytovia waxay sidoo kale horumarinaysaa musharraxa EGFR CAR iNK intracranial si ay u beegsato wtEGFR iyo EGFR vIII labadaba si wax looga qabto baahi caafimaad oo weyn oo ku jirta maaraynta Glioblastoma multiforme ee aan hadda la daweyn karin.

Cytovia waxay la samaysatay iskaashi machadyo tacliimeed iyo la-hawlgalayaal warshadeed oo ay ku jiraan Cellectis for TALEN® tafatirka hiddasidaha. Tafatirka hidda-sidaha TALEN® waa tignoolajiyad ay hormood u tahay oo ay maamusho Cellectis, oo ah shirkad heer caalami ah oo tignoolajiyada bayoolajiga ah iyada oo adeegsanaysa aaladeeda tafatirka hidda-wadaha si ay u horumariso daaweynta unugyada nolosha badbaadinta iyo hidda-wadaha. Shatiyada tafatirka hidda-sidaha TALEN® ee ay maamusho Cellectis ee goobta iNK iyo CAR-iNK waxa shati ka haysta Cellectis by Cytovia iyo Cytovia waxay haysataa horumarinta caalamiga ah iyo xuquuqda ganacsi ee shatiyadan.

Horumarrada la Qorsheeyay iyo Isticmaalka Faa'iidooyinka

Dakhliga laga helo meelaynta gaarka ah ("PIPE"), lacagaha ku jira koontada kalsoonida ee Isleworth (net of redemptions), iyo dakhliga laga helo maalgelinta kale ee la filayo, wadarta guud ee ilaa boqol milyan oo doolar, waxay siin doontaa Cytovia raasamaal ilaa 2 sanado si loo sii horumariyo hiddo-wade-tafatirka iNK iyo Flex-NK™ tignoolajiyada hawlgelinta unugga. Cytovia waxa ay qorshaynaysaa in ay diiradda saarto arrimo badan oo muhiim ah, oo ay ku jiraan:

• Soo xeraynta labada IND ee ugu horreeya Flex-NK™ CYT-303 iyo iNK CYT-100

• Bilowga Wajiga I/II ee tijaabooyinka caafimaad si loo qiimeeyo CYT-303 iyo CYT-100, kaligood iyo isku darka, daaweynta HCC

Helitaanka iyo soo bandhigida xogta daawaynta bilowga ah ee CYT-303 iyo CYT-100 gudaha HCC

• U xaraynta IND-yada CYT-150 iyo CYT-503 iyo bilawga tijaabooyinka caafimaad ee Wajiga I/II

Sii wadida kobcinta tignoolajiyada iNK & Flex-NK ™ iyo horumarinta dhuumaha iyada oo la adeegsanayo musharaxiin badan oo daaweyn ah